Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
parkinson's neuritis neuralgia myasthenia gravis lactic acidosis ataxia seizure tinnitus migraine hypotoniaYour Article Summary
See Latest ArticlesThe Correlation and Prognostic Significance of Mgmt Promoter Methylation and Mgmt Protein in Glioblastomas
Neurosurgery, 10/22/09
Cao VT et al. – The authors report the feasibility of using MSP combined with immunohistochemical staining as a prognostic factor. The results of the present study suggest that MGMT promoter methylation in combination with negative MGMT expression might be a good prognostic factor in patients with glioblastoma.
Related Articles
Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme
Journal of Neuro-Oncology, 10/28/09
Relevance Score: 88%
Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment
Clinical Cancer Research, 10/01/09
Relevance Score: 88%
Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes
Cancer, 11/12/09
Relevance Score: 87%
Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression
Clinical Cancer Research, 10/06/09
Relevance Score: 87%
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme
Journal of Neuro-Oncology, 10/01/09
Relevance Score: 87%
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A heritable predisposition to pituitary tumors
Pituitary, 12/18/09
Temozolomide (Temodar) and capecitabine (Xeloda) treatment of an aggressive corticotroph pituitary tumor
Pituitary, 12/18/09
Complete percutaneous treatment of vertebral body tumors causing spinal canal compromise using a transpedicular cavitation, cement augmentation, and radiosurgical technique
Neurosurgical Focus, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor